flanders.bio provides you with insights in the vibrant life sciences sector

 

News from flanders.bio and its members

flanders.bio is looking for a Sr. Business Developer

flanders.bio is de clusterorganisatie voor de life sciences en biotechnologiesector in Vlaanderen, een dynamische ledenorganisatie van meer dan 350 bedrijven & organisaties. Sinds 2018 werkt flanders.bio samen met DSP Valley en Medtech Flanders in het kader van een nieuw clusterinitiatief genaamd flanders.health. Om sneller innovatieve gezondheidsoplossingen te bedenken is het belangrijk dat de spelers over de technologische (life sciences, digital sciences en medische technologieën) en functionele silo’s (preventie, diagnose, behandeling en zorg) samenwerken. flanders.health wil uitgroeien tot een actief samenwerkingsplatform tussen stakeholders doorheen het hele ecosysteem (bedrijven, academische spelers, ziekenhuizen en zorgverleners, patiënten/consumenten en overheid), met faciliterende innovatiezones die de hele waardeketen kunnen innoveren tot implementeerbare “end-to-end”-oplossingen.

People | 13 September 19
Read more
13
Sep
2019

flanders.bio is looking for a Sr. Business Developer

flanders.bio is de clusterorganisatie voor de life sciences en biotechnologiesector in Vlaanderen, een dynamische ledenorganisatie van meer dan 350 bedrijven & organisaties. Sinds 2018 werkt flanders.bio samen met DSP Valley en Medtech Flanders in het kader van een nieuw clusterinitiatief genaamd flanders.health. Om sneller innovatieve gezondheidsoplossingen te bedenken is het belangrijk dat de spelers over de technologische (life sciences, digital sciences en medische technologieën) en functionele silo’s (preventie, diagnose, behandeling en zorg) samenwerken. flanders.health wil uitgroeien tot een actief samenwerkingsplatform tussen stakeholders doorheen het hele ecosysteem (bedrijven, academische spelers, ziekenhuizen en zorgverleners, patiënten/consumenten en overheid), met faciliterende innovatiezones die de hele waardeketen kunnen innoveren tot implementeerbare “end-to-end”-oplossingen.

11
Sep
2019

Science for Health: Wat ontbreekt in België om de échte top in celtherapie te bereiken?

De Belgische onderzoekscentra, biotech en farma behoren tot de wereldtop. Vandaag worden ze geconfronteerd met nieuwe uitdagingen zoals de complexiteit van de behandelingen, en hoe deze efficiënt en snel bij de patiënt te krijgen. En dit allemaal zonder dat het regelgevende kader achterop hinkt.

10
Sep
2019

iTeos Therapeutics Announces New Scientific Advisory Board Members

iTeos Therapeutics SA (iTeos), a privately-held biotechnology company developing novel cancer immunotherapies, today announced that it has added four new world-leading experts in oncology, immunology, and drug discovery and development to its Scientific Advisory Board (SAB): Gordon Freeman, William Hahn, Ben Stanger and Matt Vander Heiden. The SAB will support the development of iTeos’ pipeline of clinical and preclinical assets targeting key mechanisms of immunosuppression, in order to transform the lives of people living with cancer.

10
Sep
2019

Celyad Announces Launch of Proposed Global Offering

Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, announced today that it intends to offer and sell, subject to market and other conditions, up to 2,000,000 ordinary shares in a global offering, which is comprised of an offer of ordinary shares in the form of American Depositary Shares (“ADSs”) in the United States, Canada and certain countries outside of Europe (the “U.S. offering”), and an offer of ordinary shares in Europe and certain countries outside of the United States and Canada in a concurrent private placement (the “European private placement” and, together with the U.S. offering, the “global offering”). Investors other than qualified investors under applicable law will not be eligible to participate in the ordinary share private placement. Each ADS offered in the U.S. represents the right to receive one ordinary share.

9
Sep
2019

Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a Novel, Potent Plasma Kallikrein Inhibitor for DME

Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease, today reported additional positive topline data from a Phase 1 study with THR-149, a novel, potent, plasma kallikrein (PKal) inhibitor for the treatment of Diabetic Macular Edema (DME).

13
Sep
2019

flanders.bio is looking for a Sr. Business Developer

flanders.bio is de clusterorganisatie voor de life sciences en biotechnologiesector in Vlaanderen, een dynamische ledenorganisatie van meer dan 350 bedrijven & organisaties. Sinds 2018 werkt flanders.bio samen met DSP Valley en Medtech Flanders in het kader van een nieuw clusterinitiatief genaamd flanders.health. Om sneller innovatieve gezondheidsoplossingen te bedenken is het belangrijk dat de spelers over de technologische (life sciences, digital sciences en medische technologieën) en functionele silo’s (preventie, diagnose, behandeling en zorg) samenwerken. flanders.health wil uitgroeien tot een actief samenwerkingsplatform tussen stakeholders doorheen het hele ecosysteem (bedrijven, academische spelers, ziekenhuizen en zorgverleners, patiënten/consumenten en overheid), met faciliterende innovatiezones die de hele waardeketen kunnen innoveren tot implementeerbare “end-to-end”-oplossingen.

11
Sep
2019

Science for Health: Wat ontbreekt in België om de échte top in celtherapie te bereiken?

De Belgische onderzoekscentra, biotech en farma behoren tot de wereldtop. Vandaag worden ze geconfronteerd met nieuwe uitdagingen zoals de complexiteit van de behandelingen, en hoe deze efficiënt en snel bij de patiënt te krijgen. En dit allemaal zonder dat het regelgevende kader achterop hinkt.

10
Sep
2019

iTeos Therapeutics Announces New Scientific Advisory Board Members

iTeos Therapeutics SA (iTeos), a privately-held biotechnology company developing novel cancer immunotherapies, today announced that it has added four new world-leading experts in oncology, immunology, and drug discovery and development to its Scientific Advisory Board (SAB): Gordon Freeman, William Hahn, Ben Stanger and Matt Vander Heiden. The SAB will support the development of iTeos’ pipeline of clinical and preclinical assets targeting key mechanisms of immunosuppression, in order to transform the lives of people living with cancer.

10
Sep
2019

Celyad Announces Launch of Proposed Global Offering

Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, announced today that it intends to offer and sell, subject to market and other conditions, up to 2,000,000 ordinary shares in a global offering, which is comprised of an offer of ordinary shares in the form of American Depositary Shares (“ADSs”) in the United States, Canada and certain countries outside of Europe (the “U.S. offering”), and an offer of ordinary shares in Europe and certain countries outside of the United States and Canada in a concurrent private placement (the “European private placement” and, together with the U.S. offering, the “global offering”). Investors other than qualified investors under applicable law will not be eligible to participate in the ordinary share private placement. Each ADS offered in the U.S. represents the right to receive one ordinary share.

9
Sep
2019

Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a Novel, Potent Plasma Kallikrein Inhibitor for DME

Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease, today reported additional positive topline data from a Phase 1 study with THR-149, a novel, potent, plasma kallikrein (PKal) inhibitor for the treatment of Diabetic Macular Edema (DME).

Facts & Figures

CONSULT OUR LIFE SCIENCE DATABASE

 

Innovation is at the core of the life sciences sector and Belgium has a track record of developing ingenious ways to improve the quality of life of millions of people worldwide.

 

Not only extensive life sciences facilities support this high-level technology industry but also financial benefits for R&D companies, international collaborations that guarantee regular cash flow, world known educational systems, a promising product pipeline, and Belgium’s unique central location in Europe.

 

Belgium concentrates on a small territory (30,528 km2) more than 300 life sciences companies with biotech activities. In total, the life sciences sector employs more than 30,000 people (low bound estimation that does not take into account indirect employment generated by the sector). The majority of the companies is related to healthcare, but Belgium also has a strong representation of agricultural and industrial biotech companies.

 

The growing life sciences sector gathers 8 main Belgian universities, 19 research parks and 23 incubators, research institutes, academic hospitals, and clinical research organizations. Biotech companies have access to more than 500,000 square feet of highly flexible infrastructure.

 

Additional assets of Belgium includes: a supportive regulatory and political environment, a highly qualified and productive workforce, a competitive tax environment especially for research companies, a prominent location and an excellent logistical and business infrastructure.

Z Life Sciences

A look behind the scenes of the vibrant life sciences sector in Flanders, Belgium in 11 episodes.

1

VIB

VIB is a life sciences research institute based in Flanders. With more than 1470 scientists from over 60 countries, they perform basic research into the molecular foundations of life and they translate this research into pharmaceutical, agricultural and industrial applications.

2

imec

imec performs world-leading research in nano-electronics and creates groundbreaking innovation in application domains such as healthcare, smart cities and mobility, logistics and manufacturing, and energy. The combination of their widely acclaimed leadership in microchip technology and profound software and ICT expertise is what makes imec unique.

3

Bio Base Europe Pilot Plant

Bio Base Europe Pilot Plant is an independent, state-of-the-art facility that operates from a laboratory level to a multi-ton scale. Bio Base Europe Pilot Plant provides process development, scale-up and custom manufacturing of biobased products and processes. 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?